CRTX News and Press, Cortexyme Inc. From 07/21/21

Leading drug candidate penetrates and disrupts bacterial biofilms, a key feature for efficacy in treating P. gingivalis driven disease Atuzaginstat reverses alveolar bone loss in mice after oral P. gingivalis infection at doses relevant for therapeutic efficacy in periodontal ...

“Getting to the Root Cause of Alzheimer’s Disease: An Innovative, Upstream Approach for Disease Modification” Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quar...

Part 1 to be held Friday July 23 at 10:00 a.m. ET: Innovation in Periodontal Disease – A Major Unmet Medical Need Part 2 to be held Friday July 30 at 10:00 a.m. ET: Innovation in Alzheimer's Disease – Getting to the Root Cause of Neurodegeneration Corte...

Biogen's Alzheimer's drug approval creates major controversy. Effects of this approval on other companies and the Alzheimer's drug market are discussed. Investors can best capitalize off of Biogen's approval by looking for lesser-known and less expensive companies that will likely...

Baseline demographic and biomarker data reinforce appropriate patient population enrolled ahead of top-line data expected in fourth quarter 2021 Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with topline data expected in th...

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris Lowe, the company’s chief operating officer a...

Cortexyme (CRTX): Q1 GAAP EPS of -$0.78 beats by $0.02.Cash, cash equivalents, and short and long-term marketable securities as of March 31, 2021 were $170.8 million and include approximately $117.6 million of net proceeds raised in Cortexyme’s private placement offering completed in F...

Top-line data from 643-subject Alzheimer’s disease pivotal GAIN Trial expected in fourth quarter 2021 Top-line data from 233-subject periodontal disease Phase 2 REPAIR sub-study of the GAIN Trial expected in fourth quarter 2021 COR588 on track to initiat...

Shares of Cortexyme, Inc. plunged 35% on the news that the FDA had placed its pivotal Alzheimer’s Phase 2/3 trial on a partial clinical hold due to liver issues. The same therapy (atuzaginstat) is set to enter a Phase 2 trial for Parkinson’s disease in 3Q21. With a u...

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Chris Lowe, the company’s chief operating officer ...